Sheffield Pharmaceuticals Inc. has retained Junewicz & Co. to explore strategic alternatives, including asset sales. And the research-and-development company’s chief executive officer would not rule out selling the entire property. Thomas Fitzgerald, CEO of St. Louis-based Sheffield, said a sale of the $8 million market cap company is not out of the question “if the right circumstances presented themselves,” meaning the right price.
To read the entire story, you must be logged in.
Please log in now or register with us.
